SARS/SARS-CoV-2 Nucleocapsid Monoclonal Antibody (05) | Invitrogen MA5-29981 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

SARS/SARS-CoV-2 Nucleocapsid Monoclonal Antibody (05)

catalog :

MA5-29981

quantity :

100 uL

price :

US 470.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

reactivity :

SARS-CoV-2

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

citations: 13

Reference
Wang Y, Li P, Xu L, de Vries A, Rottier R, Wang W, et al. Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response. iScience. 2023;26:107631 pubmed publisher
Dabrowska A, Botwina P, Barreto Durán E, Kubisiak A, Obloza M, Synowiec A, et al. Reversible rearrangement of the cellular cytoskeleton: A key to the broad-spectrum antiviral activity of novel amphiphilic polymers. Mater Today Bio. 2023;22:100763 pubmed publisher
Diallo I, Jacob R, Vion E, Kozak R, Mossman K, Provost P. Altered microRNA Transcriptome in Cultured Human Airway Cells upon Infection with SARS-CoV-2. Viruses. 2023;15: pubmed publisher
Hajnik R, Plante J, Liang Y, Alameh M, Tang J, Bonam S, et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci Transl Med. 2022;14:eabq1945 pubmed publisher
Wang L, Kainulainen M, Jiang N, Di H, Bonenfant G, Mills L, et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. Nat Commun. 2022;13:4350 pubmed publisher
Pohl M, Martin Sancho L, Ratnayake R, White K, Riva L, Chen Q, et al. Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity. ACS Infect Dis. 2022;8:1265-1279 pubmed publisher
Richard D, Muthuirulan P, Aguiar J, Doxey A, Banerjee A, Mossman K, et al. Intronic regulation of SARS-CoV-2 receptor (ACE2) expression mediated by immune signaling and oxidative stress pathways. iScience. 2022;25:104614 pubmed publisher
Szlachcic W, Dabrowska A, Milewska A, Ziojla N, Blaszczyk K, Barreto Durán E, et al. SARS-CoV-2 infects an in vitro model of the human developing pancreas through endocytosis. iScience. 2022;25:104594 pubmed publisher
Paidas M, Sampath N, Schindler E, Cosio D, Ndubizu C, Shamaladevi N, et al. Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide. Front Pharmacol. 2022;13:864798 pubmed publisher
Zhong C, Xia H, Adam A, Wang B, Hajnik R, Liang Y, et al. Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. NPJ Vaccines. 2021;6:139 pubmed publisher
Kruse T, Benz C, Garvanska D, Lindqvist R, Mihalic F, Coscia F, et al. Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities. Nat Commun. 2021;12:6761 pubmed publisher
Pablos I, Machado Y, de Jesus H, Mohamud Y, Kappelhoff R, Lindskog C, et al. Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. Cell Rep. 2021;37:109892 pubmed publisher
Banerjee A, El Sayes N, Budylowski P, Jacob R, Richard D, Maan H, et al. Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. iScience. 2021;24:102477 pubmed publisher

product information

Product Type :

Antibody

Product Name :

SARS/SARS-CoV-2 Nucleocapsid Monoclonal Antibody (05)

Catalog # :

MA5-29981

Quantity :

100 uL

Price :

US 470.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Virus

Applications :

ELISA: 1:1,000-1:2,000, Flow Cytometry: 1:25-1:100, Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:1,000-1:5,000, Western Blot: 1:1,000-1:10,000

Species :

Virus

Clone :

Isotype :

IgG1

Storage :

Store at 4 C short term. For long term storage, store at -20 C, avoiding freeze/thaw cycles.

Description :

SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus. The SARS-CoV-2 N protein is an abundant RNA-binding protein critical for viral genome packaging, yet the molecular details that involve this process are poorly understood. N protein contains three dynamic disordered regions that house putative transiently-helical binding motifs. The two folded domains interact minimally such that full-length N protein is a flexible and multivalent RNA-binding protein. SARS-CoV-2 causes illnesses ranging from the common cold to severe diseases.

Immunogen :

Recombinant Human SARS Coronavirus Nucleoprotein/NP Protein

Format :

Liquid

Applications w/Dilutions :

ELISA: 1:1,000-1:2,000, Flow Cytometry: 1:25-1:100, Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:1,000-1:5,000, Western Blot: 1:1,000-1:10,000

Aliases :

COVID19 Nucleocapsid; COVID-19 nucleocapsid; COVID19 Spike nucleocapsid; SARS-CoV-2 N